Royal Bank of Canada
KLRS

Royal Bank of Canada’s Kalaris Therapeutics KLRS Stock Holding History

Royal Bank of Canada’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
103
-10
-9% -$89 ﹤0.01% 7003
2025
Q4 		$1K Buy
113
+28
+33% +$179 ﹤0.01% 7092
2025
Q3 		$0 Hold
85
– – ﹤0.01% 7660
2025
Q2 		$0 Buy
+85
New +$384 ﹤0.01% 7470
2024
Q3 		– Sell
-404
Closed -$7K – 7610
2024
Q2 		$7K Buy
404
+352
+677% +$6.21K ﹤0.01% 6464
2024
Q1 		$1K Sell
52
-608
-92% -$9.92K ﹤0.01% 6897
2023
Q4 		$10K Buy
660
+288
+77% +$11.4K ﹤0.01% 6507
2023
Q3 		$18K Buy
372
+182
+96% +$12.4K ﹤0.01% 6223
2023
Q2 		$15K Buy
190
+98
+107% +$9.31K ﹤0.01% 6338
2023
Q1 		$8K Sell
92
-63
-41% -$8.03K ﹤0.01% 6430
2022
Q4 		$18K Buy
155
+138
+812% +$23.4K ﹤0.01% 6354
2022
Q3 		$3K Sell
17
-4
-19% -$623 ﹤0.01% 6939
2022
Q2 		$2K Sell
21
-71
-77% -$7.44K ﹤0.01% 7017
2022
Q1 		$14K Sell
92
-193
-68% -$38.5K ﹤0.01% 6807
2021
Q4 		$85K Buy
285
+159
+126% +$73.8K ﹤0.01% 6053
2021
Q3 		$73K Buy
126
+19
+18% +$8.8K ﹤0.01% 5931
2021
Q2 		$48K Buy
107
+4
+4% +$2.06K ﹤0.01% 6076
2021
Q1 		$56K Buy
103
+75
+268% +$63K ﹤0.01% 5814
2020
Q4 		$25K Sell
28
-661
-96% -$509K ﹤0.01% 5970
2020
Q3 		$436K Buy
+689
New +$471K ﹤0.01% 3975

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Royal Bank of Canada's KLRS Position: Q1 2026 in Review

Royal Bank of Canada reduced its Kalaris Therapeutics (KLRS) stake by 8.8% in Q1 2026, selling an estimated $89 and leaving 103 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7003.

Royal Bank of Canada first reported a position in KLRS in Q3 2020 and has held it in 20 quarters since. The position peaked at $436K in Q3 2020. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Royal Bank of Canada held 103 shares of Kalaris Therapeutics worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 10 Kalaris Therapeutics shares in Q1 2026, an estimated $89.
  • Kalaris Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7003 holding.
  • Royal Bank of Canada first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 20 quarters since.
  • Royal Bank of Canada's Kalaris Therapeutics position peaked at $436K in Q3 2020.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.